AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06168708
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline (2 ml) on the irrigation solution (placebo)
Trial: NCT06512415
Drug: 15 mcg Norepinephrine
RxNorm normalized name: norepinephrine 0.15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
Trial: NCT05937854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one or two encapsulated tablets of placebo po QD
Trial: NCT00270543
Drug: Taxotere, Fluorouracil, Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05429723
Drug: HS-10383 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for HS-10383
Trial: NCT05299203
Drug: Sapropterin dihydrochloride tablets
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
Trial: NCT06694805
Drug: CAB LA + RPV LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
Trial: NCT06694805
Drug: Oral ART
RxNorm normalized name: Aquoral Artificial Saliva Protective Oral Spra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
Trial: NCT06686576
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ⅲ：CAPEOX will be administered
Trial: NCT06612970
Drug: HB0056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB0056 Injection
Trial: NCT06612970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06706674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo administered orally once daily
Trial: NCT06706622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available saline solution
Trial: NCT05262400
Drug: PF-07220060 + PF-07104091 combination dose escalation
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07104091 and PF-07220060 will be administered orally
Trial: NCT06708260
Drug: ENN0403, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Trial: NCT06708260
Drug: ENN0403, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Trial: NCT06176040
Drug: TAVO101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVO101 IV Infusion.
Trial: NCT06708663
Drug: HX009+IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily.
Trial: NCT06712641
Drug: Gentamicin + narrow spectrum betalactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
Trial: NCT06300970
Drug: Artemether+Lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Trial: NCT06504082
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
Trial: NCT06710847
Drug: GSK4418959
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4418959 will be administered.
Trial: NCT06353269
Drug: Estrace 0.01% Vaginal Cream
RxNorm normalized name: Estrace 0.01% Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal estrogen cream, used twice per week
Trial: NCT06712407
Drug: TARPEYO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Trial: NCT04832009
Drug: Dextrose 20 % in 500 ML Injection
RxNorm normalized name: dextrose 20 % in 500 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
Trial: NCT04832009
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
Trial: NCT05110898
Drug: fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
Trial: NCT05110898
Drug: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
Trial: NCT04708964
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
Trial: NCT06671470
Drug: YZJ-1139 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose 20 mg
Trial: NCT06672653
Drug: The monoterpenoid zinc tetra-ascorbo-camphorate (C14)
RxNorm normalized name: C14-22 alcohols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
Trial: NCT05050630
Drug: TR2-ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
Trial: NCT04837482
Drug: AGN-190584
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eyedrop
Trial: NCT04837482
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eyedrop
Trial: NCT06712992
Drug: SHAM Trans-spinal Direct current stimulation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs .
Trial: NCT06693375
Drug: Iron oxide nanoparticles
RxNorm normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
Trial: NCT06693375
Drug: Iron oxide nanoparticles
RxNorm normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
Trial: NCT06693375
Drug: Iron oxide nanoparticles
RxNorm normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
Trial: NCT06693375
Drug: Iron oxide nanoparticles
RxNorm normalized name: PEGylated iron oxide nanoparticles
DrugBank: MPB-1523 (DB18334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
Trial: NCT06390982
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
Trial: NCT06390982
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
Trial: NCT05450601
Drug: HCP2102-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 2 weeks orally
Trial: NCT05450601
Drug: HPP2104-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take once daily for 2 weeks orally
Trial: NCT05450601
Drug: HCP2102-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 6 weeks orally
Trial: NCT05450601
Drug: HPP2104-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take once daily for 6 weeks orally
Trial: NCT05450601
Drug: RLD2106-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 2 weeks orally
Trial: NCT05450601
Drug: HPP2103-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take once daily for 2 weeks orally
Trial: NCT05450601
Drug: RLD2106-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 6 weeks orally
Trial: NCT05450601
Drug: HPP2103-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take once daily for 6 weeks orally
Trial: NCT06717269
Drug: NX-5948 capsule
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-5948 in capsule form
Trial: NCT05137522
Drug: Chidamide combines with VP-16 and methylprednisolone
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
Trial: NCT06717269
Drug: NX-5948 tablet
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX-5948 in tablet form
Trial: NCT05422612
Drug: Intervention A Fluoxetine Hydrochloride (HCl)
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Trial: NCT05422612
Drug: Intervention A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Trial: NCT05422612
Drug: Intervention B Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Trial: NCT05422612
Drug: Intervention C Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Trial: NCT05422612
Drug: Intervention D Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
Trial: NCT06708416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT05635084
Drug: Placebo for YN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose injection to mimic the YN001
Trial: NCT04855721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06398275
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 0.04 mL/kg
Trial: NCT05336383
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Infusion
Trial: NCT06402760
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment methods prescribed in the guidelines.
Trial: NCT04478292
Drug: mono CDDP-Group A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
Trial: NCT04478292
Drug: Consolidation (Carboplatin, Doxorubicin) -Group D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
Trial: NCT06385964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by dry powder inhalation
Trial: NCT06722417
Drug: Icalcaprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT05703282
Drug: AD-104-A
RxNorm normalized name: OLIGOPEPTIDE 104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Single-Dose, AD-104-A
Trial: NCT04762017
Drug: OCS-05 +SoC (corticosteroid) IV administration
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days
Trial: NCT06726577
Drug: TP04HN106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
Trial: NCT06733441
Drug: TLN-254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
Trial: NCT06733441
Drug: TLN-254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLN-254 will be administered orally at a specified dose on specified days.
Trial: NCT05628467
Drug: Antidepressive Agents
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
Trial: NCT06738108
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase IV infusion
Trial: NCT02811133
Drug: Inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive inositol
Trial: NCT05901714
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05701436
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Trial: NCT04951648
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
Trial: NCT06692491
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
Trial: NCT06692491
Drug: Other
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments.
Trial: NCT05701436
Drug: Oxaliplatin, Leucovorin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Trial: NCT05543343
Drug: High dose or normal dose staphylococcus albicans
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
Trial: NCT05543343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 placebo tablets 3 times daily
Trial: NCT04558918
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
Trial: NCT05239286
Drug: PVI dependant goal directed fluid therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated.
Trial: NCT04941378
Drug: OTL38
RxNorm normalized name: Fluorodeoxyglucose F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time infusion of OTL38
Trial: NCT06236841
Drug: XH-S004 tablet
RxNorm normalized name: TRENBOLONE ACETATE 200 mg / ESTRADIOL 20 mg SUBCUTANEOUS IMPLANT [Revalor XH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
Trial: NCT06236841
Drug: XH-S004 placebo tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
Trial: NCT06194201
Drug: HRS9432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing frequency: intravenously once week
Trial: NCT05934799
Drug: Plavix® film-coated tablet 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.